Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia-Reference-Cited by-同舟云学术

Evaluating abbreviated induction with fludarabine, cyclophosphamide, and dose-dense rituximab in elderly patients with chronic lymphocytic leukemia

Published:2015-09-28 Issue:2 Volume:57 Page:328-334
ISSN:1042-8194
Container-title:Leukemia & Lymphoma
language:en
Short-container-title:Leukemia & Lymphoma

Author:

Dartigeas Caroline,Van Den Neste Eric,Berthou Christian,Maisonneuve Hervé,Leprêtre Stéphane,Dilhuydy Marie-Sarah,Béné Marie-Christine,Nguyen-Khac Florence,Letestu Rémi,Cymbalista Florence,De Guibert Sophie,Aurran Thérèse,Laribi Kamel,Vilque Jean-Pierre,Tournilhac Olivier,Delmer Alain,Feugier Pierre,Cazin Bruno,Michallet Anne-Sophie,Lévy Vincent,Troussard Xavier,Delepine Roselyne,Tavernier Elsa,Colombat Philippe,Leblond Véronique

Publisher

Informa UK Limited

Subject

Cancer Research,Oncology,Hematology

Link

http://www.tandfonline.com/doi/pdf/10.3109/10428194.2015.1063139

Reference34 articles.

1. Early Results of a Chemoimmunotherapy Regimen of Fludarabine, Cyclophosphamide, and Rituximab As Initial Therapy for Chronic Lymphocytic Leukemia

2. Addition of rituximab to fludarabine may prolong progression-free survival and overall survival in patients with previously untreated chronic lymphocytic leukemia: an updated retrospective comparative analysis of CALGB 9712 and CALGB 9011

3. Addition of rituximab to fludarabine and cyclophosphamide in patients with chronic lymphocytic leukaemia: a randomised, open-label, phase 3 trial

4. Rituximab, Fludarabine, Cyclophosphamide, and Mitoxantrone: A New, Highly Active Chemoimmunotherapy Regimen for Chronic Lymphocytic Leukemia

Cited by 7 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Measurable residual disease in chronic lymphocytic leukemia: expert review and consensus recommendations;Leukemia;2021-06-24

2. Fludarabine-Cyclophosphamide-Rituximab Treatment in Chronic Lymphocytic Leukemia, Focusing on Long Term Cytopenias Before and After the Era of Targeted Therapies;Pathology and Oncology Research;2021-04-27

3. Prognostic value of high-sensitivity measurable residual disease assessment after front-line chemoimmunotherapy in chronic lymphocytic leukemia;Leukemia;2020-09-15

4. Obinutuzumab and ibrutinib induction therapy followed by a minimal residual disease-driven strategy in patients with chronic lymphocytic leukaemia (ICLL07 FILO): a single-arm, multicentre, phase 2 trial;The Lancet Haematology;2019-09

5. Oncology nurse phone calls halve the risk of reduced dose intensity of immunochemotherapy: results of the randomized FORTIS study in chronic lymphocytic leukemia.;Annals of Hematology;2019-02-18